Pathogenesis of Acute Leukemia, Lymphoproliferative Disorders, and Myeloproliferative Disorders
Overview
- Phase
- Not Applicable
- Intervention
- blood draw, bone marrow procedure, or tissue biopsy
- Conditions
- Acute Leukemia
- Sponsor
- OHSU Knight Cancer Institute
- Enrollment
- 5000
- Locations
- 1
- Primary Endpoint
- Identify and determine the frequency of mutations causing aberrant signaling pathway function in patients with acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN)
- Status
- Enrolling By Invitation
- Last Updated
- 2 months ago
Overview
Brief Summary
The cause of blood and bone marrow cancers is poorly understood; however, most research focuses on how cancer cells grow and develop. Because the causes of these cancers are unknown, current treatments may be unnecessarily harsh and often do not provide a cure. Identifying the causes of blood cancers would allow for the development of treatments that are more likely to provide a cure. To find the causes of blood and bone marrow cancers, we will look for specific cancer cell abnormalities that are responsible for cancer cell growth. We will then look to see if drugs that can reverse these abnormalities can kill cancer cells.
Investigators
Cristina Tognon
Scientific Director
OHSU Knight Cancer Institute
Eligibility Criteria
Inclusion Criteria
- •Suspected or confirmed diagnosis of AL, LPD, MDS, or MPD
- •Male or female of all ages
- •Willing and able to sign informed consent
- •Willing guardian consent for participants under 18 years of age
Exclusion Criteria
- •No suspected or confirmed diagnosis of acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), or myeloproliferative diseases (MPD)
Arms & Interventions
Blood Draw
Intervention: blood draw, bone marrow procedure, or tissue biopsy
Outcomes
Primary Outcomes
Identify and determine the frequency of mutations causing aberrant signaling pathway function in patients with acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN)
Time Frame: After laboratory analyses are complete. Lab samples are collected at the time of a scheduled blood draw, bone marrow procedure, tissue biopsy, or other visit for usual medical care
Integrated functional genomics studies (whole genome sequencing, RNAi, proteomics, drug sensitivity, expression profiling) will be used to identify aberrant signaling pathways that contribute to the formation of hematologic malignancies.